|
AstraZeneca starts Phase III program for asthma drug tralokinumab
Pharmaceutical Business Review AstraZeneca has started the Phase III program for an investigational human monoclonal antibody tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by the company's global biologics research and … |
View full post on asthma – Google News